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Purpose: We have used a genetically attenuated adenoviral
vector which expresses HSVtk to assess the possible additive
role of suicidal gene therapy for enhanced oncolytic effect of
the virus. Expression of TK was measured using a radiotracer-
based molecular counting and imaging system. Materials and
Methods: Replication-competent recombinant adenoviral vector
(Ad- E1B19/55) was used in this study, whereas replication- Δ
incompetent adenovirus (Ad- E1A) was generated as a control. Δ
Both Ad- E1B19/55-TK and Ad- E1A-TK comprise the HSVtk Δ Δ
gene inserted into the E3 region of the viruses. YCC-2 cells
were infected with the viruses and incubated with 2'-deoxy-
2'-fluoro- -D-arabinofuranosyl-5-iodouracil (I-131 FIAU) to β
measure amount of radioactivity. The cytotoxicity of the
viruses was determined, and gamma ray imaging of HSVtk
gene was performed. MTT assay was also performed after
GCV treatment. Results: On gamma counter-analyses, counts/
minute (cpm)/ g of protein showed MOIs dependency with μ Δ
E1B19/55-TK infection. On MTT assay, Ad- E1B19/55-TK Δ
led to more efficient cell killing than Ad- E1A-TK. On plate Δ
imaging by gamma camera, both Ad- E1B19/55-TK and Ad- Δ
E1A-TK infected cells showed increased I-131 FIAU uptake Δ
in a MOI dependent pattern, and with GCV treatment, cell
viability of E1B19/55-TK infection was remarkably reduced Δ
compared to that of Ad- E1A-TK infection. Δ Conclusion:
Replicating Ad- E1B19/55-TK showed more efficient TK Δ
expression even in the presence of higher-cancer cell killing
effects compared to non-replicating Ad- E1A-TK. Therefore, Δ
GCV treatment still possessed an additive role to oncolytic
effect of Ad- E1B19/55-TK. The expression of TK by Δ
oncolytic viruses could rapidly be screened using a radiotracer-
based counting and imaging technique.
Key Words: Oncolysis, adenovirus, thymidine kinase, gene
therapy, radiotracer
INTRODUCTION
Adenoviral vectors have great gene transfer
efficiency of in both in vitro and in vivo settings,
and have been used for a variety of gene therapy
applications.
1-3 Of the adenoviral vectors, replica-
tion-incompetent adenovirus has demonstrated
promises as anticancer agents delivering various
transgenes to cancer cells in preclinical studies.
However, studies using replication-incompetent
adenovirus have not shown benefits in clinical
patients as in preclinical models.
4 One of the
major limitations in replication-incompetent ad-
enovirus is that anticancer therapeutic effects of
the viral vectors are only limited primarily to
those infected cells within solid tumors. Therefore,
many genetically modified replication-competent
adenoviruses have developed to selectively repli-
cate in cancer cells. The life cycle of replication-
competent adenoviruses results in lysis of the
infected cells, spread into adjacent cells for further
viral multiplication, and improving treatment
efficacy.
In spite of safety and feasibility of treatment,
the low potency of replication-competent selective
adenoviral vectors has been problematic,
5 and the
incorporation of therapeutic transgenes such as
HSVtk (herpes simplex-1 thymidine kinase) has
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been developed as an alternative to improve
anticancer efficacy in cancer gene therapy.
6 HSVtk
is a well-known enzyme that converts prodrug
ganciclovir (GCV) into a cytotoxic metabolite. The
oncolysis caused by a replicating virus and
suicide/prodrug gene therapy that uses HSVtk
gene to sensitize tumors to ganciclovir (GCV)
have been reported to compliment each other in
increasing the potency of anticancer effects and
treatment outcome. In contrast to some promising
results, several studies have shown no additive
effect of GCV in the context of highly potent
oncolysis mediated by highly effective infectivity-
enhanced viruses.
7 The effect of GCV seems to be
different depending on the potency of oncolysis in
differently modified vectors. Rapid screening
system to assess the amount of transgene expres-
sion by oncolytic viruses can be useful to decide
the use or timing of GCV treatment for newly
designed vectors.
In this study, we have used a genetically
attenuated adenoviral vector which expresses
HSVtk to assess the possible additive role of
suicidal gene therapy to the enhanced oncolytic
effect of the genetically engineered virus. The
expression of transgene was qualitatively and
quantitatively measured using a radiolabeled
substrate which can be used both in vitro and in
vivo for preclinical and clinical research.
MATERIALS AND METHODS
Cell lines and culture
A human-transformed embryonic kidney cell
line expressing the adenoviral E1 region (HEK293)
and human gastric adenocarcinoma cell line
(YCC-2) were used in this study. The cells were
maintained in Dulbecco's modified Eagle's medium
(DMEM; GIBCO-BRL, Grand Island, NY, USA)
supplemented with 10% fetal bovine serum
(GIBCO-BRL) and penicillin-streptomycin (100
IU/mL) in humidified atmosphere of 95% air and
5% CO2 at 37 .
Adenoviral vectors
A replication-competent recombinant adenovi-
ral vector (Ad- E1B19/55) containing normal E1A Δ
but deleting E1B19 kD and E1B-55 kD was con-
structed. A replication-incompetent adenovirus
(Ad- E1A) deleting the whole E1 region was also Δ
generated as a control. Both Ad- E1B19/55-TK Δ
and Ad- E1A-TK comprise the HSVtk gene in Δ -
serted into the E3 region of Ad- E1B19/55 and Δ
Ad- E1A, respectively. The recombinant adeno Δ -
viruses were propagated in 293 cells and purified
by CsCl equilibrium centrifugation. Purified
virion preparations were dialyzed against 10 mM
phosphate-buffered saline (PBS)- 4% sucrose and
finally stored at - 80°C. The number of viral
particles was calculated by measuring optical
density at 260 nm using a conversion factor of 1.1
× 10
12 viral particles/mL/absorbance unit. The
multiplicity of infection (MOI) was calculated
from viral particle numbers.
PCR analysis of TK expressing adenoviruses
Generated adenoviruses were lysed with pro-
teinase K, and then viral DNA was isolated with
a genomic isolation kit (Qiagene, Santa Clarita,
CA, USA). PCR was accomplished using 2 kinds
of E1- and HSVtk-specific primer sets, and the
expected sizes of PCR products were 479 and 700
bp, respectively. The PCR product fragments were
separated by 1% agarose gel electrophoresis and
visualized by UV fluorescence.
Radiolabeling
The 2'-deoxy-2'-fluoro- -D-arabinofuranosyl-5- β
iodouracil (FIAU) and the radiolabeling precursor,
2’-deoxy-2’-fluoro- -D-arabinofuranosyluracil β
(FAU) were obtained from Futurechem (Incheon,
Korea). FAU was radioiodinated with I-131 and
purified by HPLC. After vacuum dry, I-131 FIAU
was further tested for purity by HPLC analyses
and a purity of > 95% was assured in this study.
Measurement of TK expression by I-131 FIAU and
gamma counter
All experiments were conducted in triplicate in
this study. Expression of TK resulting from
adenoviral infection was evaluated in YCC-2 cells.
The cells were seeded at 5 × 10
4 cells/well onImaging of Viral Thymidine Kinase Gene Expression
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24-well plates. Twenty four hours later, the cells
were infected with a range of titers (1 MOI to 40
MOI, in triplicate) of Ad- E1B19/55-TK or Ad- Δ Δ
E1A-TK for 24 to 72 hours. After washing with
PBS, the cells were incubated with I-131 FIAU (4μ
Ci/well) for 4 hours. In additional wells, I-131
FIAU was added without infection of virus or
only cells were incubated without virus and
radiotracer.
After 4 hours of incubation, the cells were
washed twice with PBS, and 200 L of lysis buffer μ
was added to each cell for 1 hour. And the lysed
cells were harvested to measure the amount of
radioactivity by gamma counter (Wallac 148
wizrad 3, Perkin Elmer, Finland). In addition, the
amount of protein content was also measured by
BCA protein assay to normalize radioactivity to
protein content in the wells.
MTT assay after Ad- E1B19 Δ / 55-TK or Ad- E1A- Δ
TK infection
The cytotoxicity of adenoviruses was determined
by MTT (Sigma, St. Louis, MO, USA) assay which
measures the conversion of the tetrazolium salt
MTT (3-(4,5-dimethylthiazolyl-2)-2,5-diphenylte-
trazolium bromide) to formazan. YCC-2 cells were
seeded at 5 × 10
4 cells per well on 24-well plates.
After 24 hours of plating, the cells were infected
with a range of titers (1 MOI to 40 MOI, in
triplicate) of Ad- E1B19/55-TK or Ad- E1A-TK Δ Δ
for 24 to 72 hours. At the indicated times postin-
fection, 200 L of MTT in PBS (1 μ mg/mL) was
added to each well and incubated for 4 hours at
37 . Then, the supernatant was discarded, and
the precipitate was dissolved in 200 L of dimethyl μ
sulfoxide (DMSO) to dissolve MTT formazan
crystals. Finally, plates were read on a microplate
reader at 540 nm.
Gamma ray imaging using I-131 FIAU after Ad-
E1B19 Δ / 55-TK or Ad- E1A-TK infection Δ
For gamma ray imaging of HSVtk gene expres-
sion, YCC-2 cells were seeded on 24-well plates (1
× 10
5 cells/well) and cultured overnight. Then, the
cells were infected with Ad- E1B19/55-TK or Ad- Δ
E1A-TK at MOIs of 1, 10, and 40 for 48 hours. Δ
After washing with PBS, the cells were then
incubated with I-131 FIAU (4 Ci/well) for 4 μ
hours. In additional triplicate wells, I-131 FIAU
was added without infection of virus. Following
incubation, the plates were washed 3 times with
PBS and imaged with gamma camera equipped
with a high-energy, parallel-hole collimator using
a 512 × 512 matrix size for 30 minutes. After
imaging, the cells were lysed and harvested to
measure the amount of radioactivity by gamma
counter. The counts in each well were normalized
to protein content in the well.
Combination treatment with Ad- E1B19 Δ / 55-TK
or Ad- E1A-TK and GCV Δ
GCV was purchased from Roche (Espoo,
Finland) and 50 mg/mL stock solution of GCV in
sterilized water was diluted in growth media
before use. YCC-2 cells were seeded on 24-well
plates at 1 × 10
5 cells/well 24 hours prior to infec-
tion. The cells were infected with a range of titers
(1 MOI to 40 MOI, in triplicate) of Ad- E1B19/ Δ
55-TK or Ad- E1A-TK for 48 hours. At 48 hours Δ
postinfection, GCV was added at final concen-
trations of 100 g/mL. The cells were incu μ bated at
37 for additional 3 days, and MTT assay was
performed to measure the degree of cell viability.
RESULTS
Generation and characterization of adenoviruses
expressing HSVtk gene
To generate adenoviruses expressing HSVtk
gene, we generated E1-deleted replication-incom-
petent Ad (Ad- E1A-TK) and replication com Δ -
petent Ad (Ad- E1B19/55-TK). To verify each Δ
adenovirus, viral DNA was isolated and sub-
sequently used for PCR amplification with E1-
and TK-specific primer sets (Fig. 1). As expected
with the E1A-specific primer set, PCR generated
a DNA fragment of 479 bp from replication com-
petent Ads (Ad- E1B19/55 and Ad- E1B19/55- Δ Δ
TK) but replication incompetent Ads (Ad- E1A Δ
and Ad- E1A-TK) were not detected. Also, with Δ
the TK-specific primer set, PCR generated a DNA
fragment of 700 bp from adenoviruses expressing
HSVtk, Ad- E1-TK and Ad- E1B19/55-TK. This Δ ΔFig. 1. Characterization of adenoviruses expressing HSVtk
gene. (A) Specific primer sets corresponding to E1 and
HSVtk gene are shown below the diagram of E1 and E3
region of adenovirus genome, and each expected size of
PCR products is 479 bp and 700 bp, respectively. (B) PCR
product analysis of Ad- E1A, Ad- E1A-TK, Ad- Δ Δ Δ
E1B19/55, and Ad- E1B19/55-TK. The presence of each Δ
PCR product verified the expression of the E1A gene and
the insertion of HSVtk gene.
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result indicated that replication competent Ads
(Ad- E1B19/55 and Ad- E1B19/55-TK) express Δ Δ
E1A and Ad- E1-TK and Ad- E1B19/55-TK Δ Δ
express effectively HSVtk gene.
Measurement of TK expression by I-131 FIAU and
gamma counter
YCC-2 cells were infected with a range of titers
(1 MOI to 40 MOI, in triplicate) of Ad- E1B19/ Δ
55-TK or Ad- E1A-TK for 24 to 72 hours to Δ
measure the level of TK expression using I-131
FIAU (Fig. 2). On gamma counter analyses of
lysed cells, cpm/ g of protein showed MOIs μ
dependency with a linear increase from 1 to 40
MOI at all time points with E1B19/55-TK infec Δ -
tion. However, with Ad- E1A-TK infection, cpm/ Δ
g of protein were unchanged over MOIs after 24 μ
hours of infection and slightly increased after 48
and 72 hours of infection with 40 MOI. Cpm/ g μ
of protein with E1B19/55-TK infection tended to Δ
be higher than those with Ad- E1A-TK infection Δ
at all time points. In other words, higher amounts
of TK were produced from replicating than non-
replicating viruses.
MTT assay after Ad- E1B19 Δ / 55-TK or Ad- E1A- Δ
TK infection
As an indicator of cell viability, we performed
MTT assay after Ad- E1B19/55-TK or Ad- E1A- Δ Δ
TK infection (Fig. 3). After 24 hours of infection,
both Ad- E1B19/55-TK and Ad- E1A-TK showed Δ Δ
no remarkable changes of cell viability over the
ranges of MOIs. However, after 48 hours of infec-
tion, cell viability was slightly reduced over MOIs
only with Ad- E1B19/55-TK infection. After 72 Δ
hours of infection, cell viability showed even more
MOI dependency with a linear decrease from 1 to
40 MOI with Ad- E1B19/55-TK, whereas it was Δ
slightly decreased at 40 MOI with Ad- E1A-TK Δ
infection. Ad- E1B19/55-TK led to more efficient Δ
cell killing than Ad- E1A-TK after 48 and 72 Δ
Fig. 2. Measurement of TK expression by I-131 FIAU and
gamma counter. The YCC-2 cells were infected with a
range of titers of Ad- E1B19/55-TK ( Δ ) or Ad- E1A-TK Δ
( ) for 24 to 72 hours and were incubated with I-131
FIAU. On gamma counter analyses of lysed cells, cpm/ g μ
of protein showed MOIs dependency with a linear increase
from 1 to 40 MOI at all time points with E1B19/55-TK Δ
infection. With Ad- E1A-TK infection, cp Δ m/ g of protein μ
were unchanged over MOIs after 24 hours of infection and
slightly increased after 48 and 72 hours of infection with
40 MOI. MOI, multiplicity of infection.
A
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hours of infection, and the amount of viruses
needed was lower with Ad- E1B19/55-TK for the Δ
same cytotoxicity.
Gamma ray imaging using I-131 FIAU after Ad-
E1B19/ 55-TK or Ad- E1A-TK infection Δ Δ
The cells were infected with Ad- E1B19/55-TK Δ
or Ad- E1A-TK at MOIs of 1, 10, and 40 for 48 Δ
hours for gamma ray imaging of TK expression.
The incubation time of 48 hours was selected to
allow the virus to replicate and produce enough
tansgene products, but did not yet show remark-
able cell killing effect. On plate imaging by
gamma camera, both Ad- E1B19/55-TK and Ad- Δ Δ
E1A-TK infected cells showed increased I-131
FIAU uptake in a MOI dependent pattern (Fig.
4A). At 1 MOI, there was similar I-131 FIAU
uptake between the two viruses. At 10 and 40
MOIs, uptakes of I-131 FIAU were higher with
Ad- E1B19/55-TK than those with Ad- E1A-TK. Δ Δ
The differences in uptakes of I-131 FIAU between
the 2 viral infections were larger with higher viral
titers. In this study, the quantitative results on
gamma counting for I-131 FIAU were in line with
the results on plate imaging (Fig. 4B). Although
there was no remarkable I-131 FIAU uptake in
cells without viruses and I-131 FIAU, cells treated
only with I-131 FIAU showed mild uptake.
Combination treatment with Ad- E1B19/ 55-TK or Δ
Ad- E1A-TK and GCV Δ
To evaluate if the TK/GCV system could im-
prove the efficacy of treatment in vitro, YCC-2
cells were infected with Ad- E1B19/55-TK or Ad- Δ
E1A-TK, and exposed to GCV for 3 days at 48 Δ
hours postinfection (Fig. 5). Without GCV treat-
ment, cell viability was slightly reduced only with
Ad- E1B19/55-TK infection at higher MOIs. With Δ
GCV treatment, cell viability of E1B19/55-TK Δ
infection was remarkably reduced compared to
that of Ad- E1A-TK infection. The difference in Δ
enhanced cell killing effect by the combination of
GCV treatment between the two viruses was
prominent at a viral titer of 5 or more MOIs.
When GCV was given 48 hours postinfection with
Fig. 3. MTT assay after Ad- E1B19/55-TK ( Δ ) or Ad-Δ
E1A-TK ( ) infection. The cytotoxicity was determined
after infection with a range of titers of Ad- E1B19/55-TK Δ
or Ad- E1A-TK for 24 to 72 hours. Ad- E1B19/55-TK led Δ Δ
to more efficient cell killing than Ad- E1A-TK after 48 and Δ
72 hours of infection and the amount of viruses needed
was lower with Ad- E1B19/55-TK for the same cytotoxi Δ -
city. MOI, multiplicity of infection.
Fig. 4. (A) Gamma ray imaging using I-131 FIAU after Ad-
E1B19/55-TK or Ad- E1A-TK infection. The cells were Δ Δ
infected with Ad- E1B19/55-TK or Ad- E1A-TK at MOIs Δ Δ
of 1, 10, and 40 for 48 hours. Both Ad- E1B19/55-TK and Δ
Ad- E1A-TK infected cells showed increased I-131 FIAU Δ
uptake in a MOI dependent pattern. (B) The differences in
uptakes of I-131 FIAU between the two viral infections
were larger with higher viral titers. MOI, multiplicity of
infection.
A
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40 MOIs of replicating viruses, virus alone
resulted in about 80 % of cell viability, whereas
combination treatment decreased the amount of
living cells to less than 40%.
DISCUSSION
The 2 major genes in the adenovirus E1B region,
E1B 55 kDa and E1B 19 kDa, have been used as
the targets of modification in genetically attenuated
replicating adenoviruses.
8 E1B 55 kDa inhibits p53
function and E1A induces apoptosis during viral
replication. Therefore, the deletion of E1B 55 kDa
gene in a vector system is beneficial for tumor-
selective replication and specific cytotoxicity
against p53 mutated cancer cells.
9,10 However, it is
known that E1B 55 kDa deleted adenoviruses (Ad-
E1B55) show reduced cytopathic effect, presum Δ -
ably due to the important role of E1B 55 kDa in
productive viral replication through cytoplasmic
translocation and accumulation of adenoviral
mRNA.
11,12 E1B 19 kDa gene, a homologue of bcl-2
related apoptosis inhibitors, has been a promising
target of deletion to overcome the limited
cytotoxicity of Ad- E1B55. In our previous report, Δ
adenoviral vectors with the deletions of both E1B
19 kDa and E1B 55 kDa (Ad- E1B19/55) resulted Δ
in higher viral release and greater cytopathic
effect than Ad- E1B55 in most cancer cell lines. Δ
8
In addition to increased anticancer cell killing
effect of Ad- E1B19/55, these replication-com Δ -
petent adenoviruses may have another potential
advantage of a high capacity of transgene expres-
sion.
13 Therefore, the incorporation of different
therapeutic transgenes has been tried to increase
therapeutic potency of replicating adenoviruses
for cancer gene therapy.
4,6,14 However, the use-
fulness of transgenes-inserted replicating adeno-
viruses seems to be uncertain, depending on the
effects of transgenes on productive viral replica-
tion. Constitutive expression of transgenes may
cause premature cellular toxicity and impairment
of viral replication, confounding the anticancer
effect of oncolysis.
15 The retardation of viral
replication was also reported due to transgene
production competing for the cellular resources
needed for viral amplification as well as the
impact of larger genome size on speed of viral
replication.
7 Furthermore, the efficacy of transgene
targeting prodrug treatment combined with
oncolysis by replicating adenoviruses seems con-
troversial at least in some replicating adeno-
viruses.
16 Therefore, the use of effective screening
system is needed in assessing the feasibility of
new transgene-incorporated replicating viral
vectors in prodrug combination therapy for
cancer.
In this study, we have used quantitative
molecular imaging technique using gamma ray
detection and imaging system to evaluate the
usefulness of replicating adenoviruses in combina-
tion with GCV for cancer gene therapy. The
utilization of radiolabled substrates to image
transgene products has been established as a high
capacity screening method of gene transfer to
cancer cells growing in vitro.
17 This technique has
also been directly adapted to animal models and
human beings for pre-clinical and clinical trials of
gene therapy.
18,19 Based on our results, the amount
of transgene product represented as cpm/ g of μ
protein on gamma counter system showed no
MOI dependency with Ad- E1A-TK infection Δ
until 24 hours and mild increases only at higher
viral titers with longer incubation time. However,
E1B19/55-TK infection resulted in a linear Δ
fashion of MOI dependency of transgene expres-
sion from 24 to 72 hours postinfection. MTT assay
as an indicator of cell viability showed that
replicating viruses could have earlier and higher
cytotoxicity than non-replicating viruses. Never-
Fig. 5. Combination treatment with Ad- E1B19/55-TK ( Δ )
or Ad- E1A-TK ( Δ ) and GCV. GCV was added at final
concentration of 100 g/mL at 48 hours postinfection. μ
After additional 3 days of incubation, MTT assay was
performed. Cell viability of E1B19/55-TK infection was Δ
remarkably reduced compared to that of Ad- E1A-TK Δ
infection. MOI, multiplicity of infection; GCV, ganciclovir.Imaging of Viral Thymidine Kinase Gene Expression
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theless, higher amounts of TK production were
noted with replicating than non-replicating
viruses at all time points.
The cells on plates were also imaged with a
gamma camera used in routine clinical practice.
The viruses were added for 48 hours to allow
sufficient replication and produce enough TK
without remarkable cell killing yet. On plate
imaging, both Ad- E1B19/55-TK and Ad- E1A- Δ Δ
TK infected cells showed increased I-131 FIAU
uptake in a MOI dependent pattern. The differ-
ences in uptakes of I-131 FIAU between the 2 viral
infections were larger with higher viral titers. The
results on plate imaging for I-131 FIAU were in
agreement with the results on gamma camera
imaging. It seems clear that the expression of TK
was qualitatively and quantitatively measured
under various incubation conditions using a
radiotracer based molecular imaging technique.
Differing from cells without viruses and I-131
FIAU, cells treated only with I-131 FIAU showed
mild uptake, likely due to the activity of
endogenous TK-like enzymes.
17 This information
on gamma imaging would also be helpful in
developing those prodrugs or radiotracers more
specific to viral TK.
We performed MTT assay to measure cell
viability after Ad- E1B19/55-TK or Ad- E1A-TK Δ Δ
infection. Ad- E1B19/55-TK led to more efficient Δ
cell killing than Ad- E1A-TK after 48 and 72 hours Δ
of infection, and the amount of viruses needed
was lower with Ad- E1B19/55-TK for the same Δ
cytotoxicity. The results also confirmed the use of
replicating viruses instead of non-replicating
viruses for enhanced anticancer potency like
others. However, the fraction of viable cells was
still very high (around 50%) even with the highest
viral titer of 40 MOIs of Ad- E1B19/55-TK and Δ
longest incubation time of 72 hours. Despite the
increased potency of cancer cell killing compared
to non-replicating Ad- E1A-TK, there is still need Δ
for further improvement of oncolytic profiles with
E1B19/55-TK. The deletion of E1B 55 Δ kDa could
have been attributable to the low oncolytic potency
since it plays an important role in productive viral
replication.
7,14
While E1B19/55-TK seems to have a low Δ
oncolytic potential, the high efficiency of TK
expression in spite of cytotoxicity can be useful in
combination treatment with GCV. In fact, Raki et
al recently reported that GCV might not add
antitumor activity in the context of highly potent
oncolysis.
7 We seeded cells on 24-well plates and
infected with Ad- E1B19/55-TK or Ad- E1A-TK. Δ Δ
Then, GCV was applied for 3 days at 48 hours
postinfection. Without GCV treatment, the viral
incubation time of 48 hours resulted in slightly
reduced cell viability only with Ad- E1B19/55-TK Δ
infection at higher MOIs. With GCV treatment,
the reduction of cell viability was rather remark-
able with E1B19/55-TK infection than that with Δ
Ad- E1A-TK infection. Therefore, in spite of the Δ
possibility of GCV treatment interfering with viral
replication in vitro,
20 anticancer efficacy of Ad-Δ
E1B19/55-TK in combination with GCV in this
study remains beneficial It is possible that the
enhanced anticancer activity of the oncolytic
adenovirus with HSVtk gene can include the
bystander effects of the TK/GCV system.
In conclusion, the use of a replication-com-
petent adenoviral variant of Ad- E1B19/55-TK Δ
showed more efficient TK expression even in the
presence of higher cancer cell killing effect than a
replication-incompetent adenovirus of E1A-TK. Δ
Although there have been contradictory results on
the value of GCV in combination with replication-
competent viruses, GCV treatment still possessed
an additive role to the oncolytic effect of Ad-Δ
E1B19/55-TK used in this study. Finally, we con-
firmed that the expression of transgene by on-
colytic viruses could rapidly be screened qualita-
tively and quantitatively using a radiotracer-
based counting and imaging technique which
simulated the clinical setting of disease diagnosis
and monitoring.
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